Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) Martin C. Michel,

Slides:

Advertisements

Similar presentations

Immunopathological characterization of selected mouse models of inflammatory bowel disease: Comparison to human disease Yava L. Jones-Hall, Matthew B.

Advertisements

Volume 54, Pages S135-S139 (December 1998)

Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI Clinical Therapeutics

The PSA Era is not Over for Prostate Cancer

Relationship Between Orthostatic Blood Pressure Changes and Postural Sway When Standing up from a Chair in Older Adult Females Jun Murata, Shin Murata,

Volume 52, Issue 1, Pages (July 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 49, Issue 2, Pages (February 2006)

Reversible, Non-Barrier Male Contraception: Status and Prospects

Female Urinary Incontinence in the West of Turkey: Prevalence, Risk Factors and Impact on Quality of Life Izzet Kocak, Pinar Okyay, Mehmet Dundar, Haluk.

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Volume 49, Issue 2, Pages (February 2006)

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

Validity and Reliability of a Questionnaire for Evaluating Nocturia, Nocturnal Enuresis and Sleep-Interruptions in an Elderly Population M.H. Bing, L.A.

Volume 71, Issue 4, Pages (April 2017)

Let the Games Begin (with EAU Approval)

Prostate Cancer Epidemic in Sight?

Volume 45, Issue 4, Pages (April 2004)

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

John P. Mulhall, Francesco Montorsi European Urology

Martin C. Michel European Urology Supplements

Volume 63, Issue 1, Pages (January 2013)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 47, Issue 2, Pages (February 2005)

Volume 56, Issue 3, Pages (September 2009)

A Systematic Review of Graft Augmentation Urethroplasty Techniques for the Treatment of Anterior Urethral Strictures Altaf Mangera, Jacob M. Patterson,

Volume 70, Issue 3, Pages (September 2016)

Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Mirjam Kuipers

P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes European Urology

Volume 64, Issue 4, Pages (October 2013)

Volume 72, Issue 3, Pages (September 2017)

Volume 47, Issue 5, Pages (May 2005)

Volume 70, Issue 1, Pages (July 2016)

Volume 49, Issue 6, Pages (June 2006)

Prostate Cancer Epidemic in Sight?

Volume 48, Issue 4, Pages (October 2005)

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old P. Perrin,

Trends in Hypospadias Surgery: Results of a Worldwide Survey

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Treatment of Bacterial Urinary Tract Infections: Presence and Future

The Economic Costs of Overactive Bladder in Germany

Volume 52, Issue 4, Pages (October 2007)

Volume 70, Issue 1, Pages (July 2016)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 74, Issue 5, Pages (November 2018)

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) Martin C. Michel,

Testicular Cancer Variations in Time and Space in Europe

Orthostatic function and the cardiovascular response to early mobilization after breast cancer surgery R.G. Müller, M. Bundgaard-Nielsen, H. Kehlet

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH

S.G. John, N.M. Selby, C.W. McIntyre Kidney International

European Urology is “Your” Journal

Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.

Martin Michel, Jean de la Rosette European Urology Supplements

Profile of Silodosin European Urology Supplements

LUTS and Sexual Dysfunction: Implications for Management of BPH

Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation Martin.

The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study Bob Djavan,

Testim® Gel: Review of Clinical Data

Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects Martin C. Michel, Cees Korstanje, Walter.

Heated water-based exercise training reduces 24-hour ambulatory blood pressure levels in resistant hypertensive patients: A randomized controlled trial.

Bertrand Tombal, Richard Berges

Volume 54, Pages S135-S139 (December 1998)

Importance of blood pressure control in hemodialysis patient survival

Volume 51, Issue 5, Pages (May 2007)

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Presentation transcript:

Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL) Martin C. Michel, Christopher R. Chapple European Urology Volume 49, Issue 3, Pages 501-509 (March 2006) DOI: 10.1016/j.eururo.2005.12.024 Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 1 (A) Change from preinfusion in diastolic blood pressure (DBP) following infusion of phenylephrine at 2h after the dosing of placebo, tamsulosin OCAS 0.4mg and alfuzosin XL 10mg. (B) Change from preinfusion in total peripheral resistance (TPR) following infusion of phenylephrine at 2h after the dosing of placebo, tamsulosin OCAS 0.4mg and alfuzosin XL 10mg. European Urology 2006 49, 501-509DOI: (10.1016/j.eururo.2005.12.024) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 2 (A) Percentage change from baseline in Imaxact based on the change from preinfusion in diastolic blood pressure. Data are least square means±95%CI. (B) Percentage change from baseline in Imaxact based on the change from preinfusion in total peripheral resistance. Data are least square means±95%CI. European Urology 2006 49, 501-509DOI: (10.1016/j.eururo.2005.12.024) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 3 Proportion of positive orthostatic tests (OTs) following dosing of tamsulosin OCAS 0.4mg and alfuzosin XL 10mg in elderly volunteers. European Urology 2006 49, 501-509DOI: (10.1016/j.eururo.2005.12.024) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 4 Proportion of discordant pairs showing a positive orthostatic test comparing treatment of elderly volunteers with tamsulosin OCAS 0.4mg and alfuzosin XL 10mg; ns, not significant. European Urology 2006 49, 501-509DOI: (10.1016/j.eururo.2005.12.024) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 5 Effect on vital signs on postural change following dosing with either tamsulosin OCAS 0.4mg or alfuzosin XL 10mg; (A) systolic blood pressure (SBP); (B) diastolic blood pressure (DBP). *p<0.05. European Urology 2006 49, 501-509DOI: (10.1016/j.eururo.2005.12.024) Copyright © 2006 Elsevier B.V. Terms and Conditions